IBRXImmunityBio, Inc.

$8B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47,000+4.4% YoY

Gross Profit

$3M6717.0% margin

Operating Income

-$98M-209338.3% margin

Net Income

-$96M-204736.2% margin

EPS (Diluted)

$-0.30

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$76M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$182M

Total Liabilities

$36M

Stockholders' Equity

$146M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47,000	$45,000	+4.4%
Gross Profit	$3M	$45,000	+6915.6%
Operating Income	-$98M	-$99M	+0.7%
Net Income	-$96M	-$96M	+0.2%

IBRX FY 2018 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena